Black and Hispanic Patients Use Telehealth Less Than White Patients During COVID-19 Pandemic
October 13th 2020Researchers indicated it is important to recognize these disparities that exist among racial and ethnic minorities in order to ensure routine and follow-up cancer care is delivered, even during the COVID-19 pandemic.
UroCAD Outperforms Urine Cytology in Detecting Urothelial Carcinoma
October 9th 2020This study suggested that the customized bioinformatics workflow, UroCAD, be used as a noninvasive approach for diagnosis and recurrence surveillance in patients with urothelial carcinoma prior to the use of cystoscopy.
Phase 3 PENELOPE-B Trial Fails to Meet Meet Primary End Point for HR+, HER2- Early Breast Cancer
October 9th 2020The trial did not meet its primary end point of improved invasive disease-free survival in women with hormone receptor-positive HER2-negative early breast cancer who have residual invasive disease after completing neoadjuvant chemotherapy.
Rucaparib Demonstrates Significant Antitumor Activity for Patients with Advanced Prostate Cancer
October 8th 2020A study published in the Journal of Clinical Oncology found that rucaparib can successfully treat patients with metastatic castration-resistant prostate cancer who have mutated BRCA/BRCA2 genes.
6-Month PFS for 12-Month OS Model Appears Effective for Estimating 12-Month OS
October 7th 2020Researchers suggested these findings may assist in better selection and prioritization of immune checkpoint inhibitor agents for testing in randomized clinical trials based on phase 2 single arm randomized clinical trial results.
Study Identifies Characteristics of CAR T-Cell Products Associated with Outcomes in LBCL
October 7th 2020Researchers identified molecular and cellular characteristics of anti-CD19 CAR T-cell infusion products associated with how patients with large B-cell lymphoma respond to treatment and experience adverse events.
Phase 3 CheckMate-816 Trial Meets Primary End Point in Resectable NSCLC
October 7th 2020Significantly more patients treated with nivolumab (Opdivo) plus chemotherapy before surgery demonstrated no evidence of cancer cells in their resected tissue in the trial compared to those treated with chemotherapy alone.
Jennifer L. Moss, PhD, on Cancer Mortality in Persistent Poverty Counties
October 6th 2020Moss indicated that “we need interventions in these communities to change cancer-causing behaviors, to make cancer screening more accessible, to improve treatment, and to promote quality of life and survivorship.”
Topical Immunosuppressants Drugs Don’t Increase Risk of Common Skin Cancers, Despite Warning Labels
October 5th 2020A study published in JAMA Dermatology determined that topical immunosuppressant medications used to treat adult patients with atopic dermatitis do not increase the risk of common forms of cancer despite warning labels on the packaging.
Predicting Tumor Response Using Combo of Peritumoral Radiomics Features Appears Effective
October 4th 2020A combination of peritumoral radiomics features appeared to improve the predictive performance of intratumoral radiomics to estimate pathological complete response after neoadjuvant chemoradiation in patients with esophageal squamous cell carcinoma.
Study Supports Pembrolizumab Plus Chemo as Standard of Care for PD-L1-Negative Advanced NSCLC
October 4th 2020A pooled analysis of 3 randomized controlled trials found that pembrolizumab plus chemotherapy demonstrated response and survival improvements with a manageable safety in comparison with chemotherapy alone in PD-L1‒negative advanced non-small cell lung cancer.